

BC Cancer for Transarterial Chemoembolization (TACE) of Hepatocellular Carcinoma Using Drug-Eluting Bead (DEB) Loaded with DOXOrubicin

Protocol Code

GIDEBTACE

Tumour Group

Gastrointestinal

Contact Physician

Dr. Howard Lim

Dr. Dave Liu

ELIGIBILITY:

- Hepatocellular carcinoma (HCC)
- Reviewed by a multidisciplinary panel:
 - gastroenterologist with HCC experience
 - surgeon with hepato-pancreato-biliary experience
 - interventional radiologist
- ECOG 0 or 1

EXCLUSIONS:

- Child-Pugh Class C
- Diffuse HCC (> 50% liver involvement)
- Presence of significant ascites or encephalopathy
- Portal vein thrombosis excluded by Doppler ultrasound or CT
- Bilirubin greater than 50 micrommol/L, AST/ALT greater than 5 times the ULN
- Contraindication for DOXOrubicin

TESTS:

- Biphase CT scan of abdomen within 4-8 weeks prior to the procedure
- Baseline: CBC & diff, platelets, INR, [sodium](#), [potassium](#), BUN, creatinine, bilirubin, alkaline phosphatase, [ALT](#), LDH, albumin, alpha-fetoprotein (AFP)
- Daily for 2 days post-procedure: CBC & diff, platelets, INR, [sodium](#), [potassium](#), BUN, creatinine, bilirubin, alkaline phosphatase, [ALT](#), LDH, albumin, alpha-fetoprotein (AFP)

SUPPORTIVE MEDICATIONS:

Prevention of radiographic contrast dye-mediated nephropathy

If clinically indicated:

Drug	Dose	BC Cancer Administration Guideline
sodium bicarbonate	150 mEq, 1 hour prior to procedure	IV in 1000 mL D5W at <ul style="list-style-type: none">3 mL/kg/h (max. 330 mL/h) for 1 hour prior to pre-procedure1 mL/kg*/h (max. 110 mL/h) for 6 hours during and post-procedure

**use a maximum weight of 110 kg to calculate sodium bicarbonate infusion rate*

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Drug-eluting bead loaded with DOXOrubicin	Determined at the time of review based on tumour size	Prepared and ordered by angiography and interventional radiology department

Call Dr. Howard Lim or tumour group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

1. Lammer J, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010;33:41-52.
2. Song MJ, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. *J Hepatol* 2012;57(6):1244-50.